Dr. Takakuwa from Pharmacology Business Unit to present a poster at the 99th Annual Meeting of the Japanese Pharmacological Society

2026.03.09

Dr. Takakuwa from the Pharmacology Business Unit, will deliver a poster presentation at The 99th Annual Meeting of the Japanese Pharmacological Society, to be held in Kawauchi Campus, Tohoku University, Japan.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.

Conference Name:The 99th Annual Meeting of the Japanese Pharmacological Society

Date & Time: March 16 (Mon), 2026, 13:00-14:00 (JST)

Location: Kawauchi Campus, Tohoku University, Japan

Title: Route-Dependent Central Effects and Efficacy Prediction of a Nucleic Acid Drug: Comparison of ICV and IT Administration

Presentation Summary
Large-molecule therapeutics, including nucleic acid drugs, show limited permeability across the blood–brain barrier; therefore, direct delivery methods such as intracerebroventricular (ICV) and intrathecal (IT) administration are used to target the central nervous system. In this study, focusing on the clinical relevance of IT administration, we compared CNS exposure, target gene knockdown efficiency, and tolerability of antisense oligonucleotides following single ICV or IT dosing in mice. We further examined the potential enhancement pharmacological effects through repeated IT dosing. This presentation introduced our expanded evaluation approaches for direct CNS delivery and provides foundational insights useful for designing dosing regimens.

Axcelead DDP’s Soulution
Axcelead has established a proprietary evaluation platform by leveraging its strengths in the fields of CNS disorders and nucleic acid drug discovery. Axcelead provides one-stop support from sequence design to efficacy and safety assessment. Please feel free to contact us when considering evaluation of CNS-targeted nucleic acid therapeutics.

Related Service: Oligonucleotide